Peptide nucleic acid probe-assisted paper-based electrochemical biosensor for multiplexed detection of respiratory viruses
1
Issued Date
2024-11-01
Resource Type
ISSN
00399140
Scopus ID
2-s2.0-85200142631
Journal Title
Talanta
Volume
279
Rights Holder(s)
SCOPUS
Bibliographic Citation
Talanta Vol.279 (2024)
Suggested Citation
Lomae A., Teekayupak K., Preechakasedkit P., Pasomsub E., Ozer T., Henry C.S., Citterio D., Vilaivan T., Chailapakul O., Ruecha N. Peptide nucleic acid probe-assisted paper-based electrochemical biosensor for multiplexed detection of respiratory viruses. Talanta Vol.279 (2024). doi:10.1016/j.talanta.2024.126613 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100373
Title
Peptide nucleic acid probe-assisted paper-based electrochemical biosensor for multiplexed detection of respiratory viruses
Corresponding Author(s)
Other Contributor(s)
Abstract
The similar transmission patterns and early symptoms of respiratory viral infections, particularly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza (H1N1), and respiratory syncytial virus (RSV), pose substantial challenges in the diagnosis, therapeutic management, and handling of these infectious diseases. Multiplexed point-of-care testing for detection is urgently needed for prompt and efficient disease management. Here, we introduce an electrochemical paper-based analytical device (ePAD) platform for multiplexed and label-free detection of SARS-CoV-2, H1N1, and RSV infection using immobilized pyrrolidinyl peptide nucleic acid probes. Hybridization between the probes and viral nucleic acid targets causes changes in the electrochemical response. The resulting sensor offers high sensitivity and low detection limits of 0.12, 0.35, and 0.36 pM for SARS-CoV-2 (N gene), H1N1, and RSV, respectively, without showing any cross-reactivities. The amplification-free detection of extracted RNA from 42 nasopharyngeal swab samples was successfully demonstrated and validated against reverse-transcription polymerase chain reaction (range of cycle threshold values: 17.43–25.89). The proposed platform showed excellent clinical sensitivity (100 %) and specificity (≥97 %) to achieve excellent agreement (κ ≥ 0.914) with the standard assay, thereby demonstrating its applicability for the screening and diagnosis of these respiratory diseases.